| A | B | C | D | E | F | G | H | I | J | K | L | M | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | SolvingMS.org Regenerative Trials Database Click Links for Enrollment Info | Proposed Modality | Country | MS Type For Trial | EBV Rx | Trial Phase | Phase Status | Years Until Approval | FDA Approval (est.) | Pipeline Also in Trial For | Phase Score Most Weight | Effective- ness | FDA Acceler- ation | Overall Score = Phase Score^2 xEffectiveness +Acceleration | Start date | Trial Readout Estimate | https://www.facebook.com/groups/solvingms/ | http://bit.ly/SolvingMS_Database | |||||||||||||
2 | SolvingMS.org MS Research Database | Curative & Regenerative Clinical Trials | As of: | 9/14/2026 | Total=92 | Overall Score | |||||||||||||||||||||||||
3 | Trial Finder | Enroll in Recruiting Trials! | Copyright © 2026 Solving MS - All Rights Reserved | Ph 3=14 | Ph 2=44 | Ph 1=34 | |||||||||||||||||||||||||
6 | # of trials: PPMS 32 SPMS 38 RRMS 30 ALL MS Types 17 | https://clinicaltrials.gov/study/NCT05201638 | |||||||||||||||||||||||||||||
25 | Special Reports and Resources | ||||||||||||||||||||||||||||||
26 | Accelerate Regenerative Medicine Agenda (ARMA) by Solving MS | Whitepaper: Agenda to Address the National Emergency of Infection-Associated Chronic Conditions & Autoimmune Disease. | |||||||||||||||||||||||||||||
27 | 2026 Antiviral Trials for EBV in MS | Three phase 3 clinical trials are starting in 2025 to test the repurposed drugs Spironolactone, Tenofovir Alafenamide and Famciclovir for antiviral effect against Epstein-Barr virus (EBV) in MS. | |||||||||||||||||||||||||||||
28 | History of Antivirals & Other Treatments for EBV in MS | History of research on EBV as the cause of MS and conclusive proof published Jan. 2022. Includes clinical trials of antivirals and other approaches for EBV. Also see Should I Get an EBV Test If I Have MS? | |||||||||||||||||||||||||||||
29 | Paxlovid: Epstein-Barr Virus Antiviral Effect? | Patient Reported Outcomes: Paxlovid cor Covid-19 also improved symptoms for Long Covid, MS, ME/CFS and primary EBV. Did Paxlovid reduce EBV? | |||||||||||||||||||||||||||||
30 | Supplements for Mitochondria and Myelin | An Evidence-Based Analysis of Nutritional, Lifestyle, and Cellular Interventions To Improve Mitochondrial Function and Support Myelin in MS. | |||||||||||||||||||||||||||||
31 | Brain-Regeneration for MS | AI Search Engine for all MS research studies and clinical trials. | |||||||||||||||||||||||||||||
32 | Collaborate with SolvingMS! | Join our Research Study Group! Over 2000 members tracking the research! All disease types welcome. See Pipeline column below - many theraoies treat multiple diseases. We can win this battle faster together! | |||||||||||||||||||||||||||||
33 | MS Clinical Trials | ||||||||||||||||||||||||||||||
34 | 1 | Sanofi, BTKi Tolebrutinib | ↓ Microglia Slow disability Modulate B-cells EBV-Antiviral | Many | nrSP | Treat | 3 | FDA refused approval Jan 2026 | 0.75 | 2026.75 | MS | 3 | 2.5 | Break- through Therapy | 3 | 26 | 1131 | 2020-09-24 | 2024-08-29 | 2024-08-29 | |||||||||||
35 | 2 | Immunic, IMU-838 Vidofludimus_Calcium | ↓ Microglia Astrocyte Stop progression Anti-inflammatory EBV-↓Pyrimidine | Many | RR ENSURE-1 ENSURE-2 | Treat | 3 | Recruiting | 2 | 2028 | MS UC CD | 3 | 2.75 | 25 | 1050 | 2021-11-18 | 2024-09 | 2024-09 | 2032-09 | ||||||||||||
36 | 3 | AB Sciences, Tyrosine Kinase inhibitor TKi Masitinib (MAXIMS) Trial Info May2025 | ↓Microglia ↓Mast cells Slow progression | France | naSP PP | 3 | Recruiting | 2 | 2028 | MS ALS AD C19 Asthma | 3 | 2.75 | 25 | 800 | 2022-06-28 | 2025-12 | |||||||||||||||
37 | 4 | BTKi Fenebrutinib | ↓ Microglia Stop disability Modulate B-cells EBV-Antiviral | Many | RR PP | Treat | 3 | Active, Not Recruiting | 2 | 2028 | MS | 3 | 2.75 | 25 | 2023-12-13 | 2027-05-06 | 2027-05-06 | ||||||||||||||
38 | 5 | Sanofi, Frexalimab FREVIVA Trial Info 2026 | Remyelination Immune-tolerance Slow-disability | USA QUEBEC | nrSP | Treat | 3 | Active, Not Recruiting | 3 | 2029 | MS | 3 | 2.75 | 25 | 2023-12-27 | 2028-03-24 | 2028-03-24 | Late 2028 or early 2029 | |||||||||||||
39 | 6 | Sanofi, Frexalimab FREXALT Trial Info 2026 | Remyelination Immune-tolerance Slow-disability | USA QUEBEC | RR | Treat | 3 | Active, Not Recruiting | 2.5 | 2028.5 | MS | 3 | 2.75 | 25 | 2023-12-27 | 2027-05-06 | 2027-05-06 | Late 2027 or early 2028 | |||||||||||||
40 | 7 | Sanofi, Frexalimab Subcutaneous FREXCITE Trial Info 2026 | Remyelination Immune-tolerance Slow-disability | Many | RR nrSP | Treat | 3 | Recruiting 12 month trial | 3 | 2029 | MS | 3 | 2.75 | 25 | 160 | 2026-01-14 | 2027-07-15 | 2028-11-30 | Mid 2029 | ||||||||||||
41 | 8 | FIRMS EBV - Spironolactone vs Tenofovir Alafenamide Info & Trials | EBV Antiviral | Austrailia | RR | Treat | 3 | Not yet recruiting Planned 2025 | 3 | 2029 | MS | 3 | 2.75 | 25 | |||||||||||||||||
42 | 8 | Griffith University, Spironolactone & Famciclovir for EBV Info & Trials | EBV Antiviral | Australia All States | SP PP | Treat | 3 | Recruiting | 3 | 2028 | MS | 3 | 2.75 | 25 | |||||||||||||||||
43 | 9 | Novartis, Remibrutinib BTKi Info 5 Trials | ↓Mast cells Slow progression EBV-Antiviral | Many | RR PP | Treat | 3 | Recruiting | 3 | 2029 | MS CSU MG Sjögren's | 3 | 2.75 | 25 | 800 | 2021-12-13 | 2026-04-30 | 2030-10-30 | |||||||||||||
44 | 10 | TKI Mastinib | Remyelination Slow-disability | Europe | SP PP | 3 | Active, Not Recruiting | 2 | 2028 | MS | 3 | 2.5 | 23 | 800 | 2022-06-28 | 2028-12 | 2028-12 | ||||||||||||||
45 | 11 | Clemastine for Remyelinating Internuclear Ophthalmoparesis in MS | Remyelination | Amsterdam | ALL | 3 | Recruiting or Off-label precription | 2.5 | 2028.5 | MS | 3 | 2 | 18 | 80 | 2022-08-30 | 2024-5 | 2026-11 | ||||||||||||||
46 | 12 | Octopus MS: Metformin, Clemastine, Alpha Lipoic Acid Trial | Remyelination | UK | SP PP | 3 | Recruiting or Off-label precription | 3 | 2029 | MS | 3 | 2 | 18 | ||||||||||||||||||
47 | 13 | Nervgen, NVG-291 | Axonal regeneration Neurogenesis Remyelination Neuroplasticity | USA | SCI | 3 | SCI Q2 2025 | 6 | 2032 | SCI MS AD ALS STROKE | 2 | 3 | Fast Track | 3 | 15 | 40 | 2023-08-08 | 2026-03 | 2026-04 | ||||||||||||
48 | Sanofi, Frexalimab Trial Info 2024 | Remyelination Immune-tolerance Slow-disability | Many | RR | Treat | 2 | Completed Published 2024 | 3 | 2029 | MS | 3 | 2.75 | 25 | ||||||||||||||||||
49 | 14 | Immunic, IMU-838 Vidofludimus_Calcium | Anti-inflammatory immunomodulator Neuroprotective EBV-↓Pyrimidine | Many | SP PP CALLIPER | Treat | 2 | Active, Not Recruiting | 4 | 2030 | MS UC | 2.75 | 2.75 | 21 | 450 | 2021-09-30 | 2025-01-07 | 2025-01-07 | |||||||||||||
50 | 15 | Clene, CNM-Au8 Nanogold | Remyelination Neuroregenerative Mitochondria repair | USA | RR | 2 | Completed | 3 | 2029 | MS ALS PD | 2.75 | 2.75 | 21 | ||||||||||||||||||
51 | 16 | Tisch MS Center, Stem Cells | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | USA | SP PP | 2 | Completed Published | 3.5 | 2029.5 | MS | 2.75 | 2.5 | Fast Track | 3 | 22 | ||||||||||||||||
52 | 17 | Hope Biosciences, Stem Cells | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | USA | RR | 2 | Completed 2024 Topline Results | 3 | 2029 | MS C19 LCoviD SCI PD... | 2.75 | 2.5 | RMAT | 4 | 23 | ||||||||||||||||
53 | 18 | Brainstorm, NurOwn Stem Cells | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | USA | SP PP | 2 | Completed Published | 3.5 | 2029.5 | MS ALS | 2.75 | 2.5 | Priority Review | 1 | 20 | 2023-06-01 | |||||||||||||||
54 | 19 | Hadassah, Stem Cells Video Info Trial | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | Israel | SP PP | 2 | Ph 2 Published Ph 3 Planned | 3.5 | 2029.5 | MS | 2.75 | 2.5 | 19 | ||||||||||||||||||
55 | 20 | Clene, CNM-Au8 Nanogold | Non-immunomodulatory Remyelination Neuroregenerative Mitochondria repair | USA | SP PP | 2 | Active, Not Recruiting | 3 | 2029 | MS ALS PD | 2.5 | 2.75 | 17 | ||||||||||||||||||
56 | 20 | Imcyse, Imotopes Info Trial | MBP-tolerizing | Moldova | RR | Treat | 1/2 | Unknown Status | 4 | 2030 | MS | 2 | 4 | Priority Review | 1 | 17 | 150 | 2022-04-12 | 2025-05-23 | 2025-12-31 | |||||||||||
57 | 21 | Tiziana, Foralumab Info 5/25 Trial | ↓Microglial Activity ↑T-cell balance→ ↓Glial Inflammation | USA | SP | 2 | Recruiting | 3 | 2029 | MS MSA ALS AD LC T1DM SCI | 2 | 2.75 | Fast Track | 3 | 14 | 54 | 2023-11-15 | 2025-11 | 2025-11 | ||||||||||||
58 | 22 | NeuOrphan, Diaprotectome (DITPA) | Remyelination Neuroregenerative Mitochondria repair | Greece Australia | SP PP | 2 | Planned Q3 2025 | 5.5 | 2031.5 | MS | 2 | 2.75 | 11 | 400 | 2025 | ||||||||||||||||
59 | 23 | SMART-MS Stem Cells | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | Norway | SP PP | 2 | Active, Not Recruiting | 3.5 | 2029.5 | MS | 2 | 2.5 | 10 | 18 | 2021 | ||||||||||||||||
60 | 24 | TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in RRMS (TOTEM-RRMS) Trial | Remyelination Neuroregenerative | France | RR | 2 | Recruiting | 4 | 2030 | MS | 2 | 2 | 8 | 40 | 2019-10-29 | 2027-12-01 | 2027-12-01 | ||||||||||||||
61 | 25 | Biogen, BTKi BIIB091 Trial Info | Modulate B-cells Slow progression EBV-Antiviral | USA | RR | 2 | Completed | 4 | 2030 | MS | 2 | 2.5 | 10 | 270 | 2023-07-25 | 2025-07-10 | 2026-11-09 | ||||||||||||||
62 | 26 | Metformin & AMPK - 7 Trials | Remyelination | Many | RR | 2 | Recruiting or Off-label precription | 3 | 2029 | MS LCovid ME/CFS | 2 | 2 | Fast Track | 3 | 11 | 36 | 2020-09-22 | 2027-02-22 | 2027-05-31 | ||||||||||||
63 | 27 | Combination Therapies: Pioglitazone, Clemastine, Dantrolene, Pirfenidone (TRAP-MS) Trial | Combination therapies to target pathogenic processes in MS. | USA MD | SP PP | 2 | Recruiting | 4 | 2030 | MS | 2 | 1.5 | 6 | 250 | 2017-08-11 | 2026-01-01 | 2029-01-01 | ||||||||||||||
64 | 28 | Clemastine Fumarate as a Myelin Repair Therapy (ReVIVE) Trial | Remyelination | USA UCSF | RR | 1/2 | Recruiting | 4 | 2030 | MS | 2 | 1.5 | 6 | 74 | 2023-08-01 | 2025-06-01 | 2025-06-01 | ||||||||||||||
65 | 29 | BALANCE-MSS-1 for Spasticity Info Trial | Spasticity relief | Many | ALL | 2 | Recruiting | 5 | 2031 | MS | 2 | 1.5 | 6 | 200 | 2025-06-05 | 2026-11-18 | 2027-01-27 | ||||||||||||||
66 | 30 | Urolithin A (Mitopure) on Cognitive Function Trial | Mitochpndria Cognitive decline Brain Fog | USA | ALL | Pilot | Recruiting | Available Now OTC | Aging | 1 | 1.5 | 1 | 650 | 2025-07-29 | 2025-12 | 2026-12 | |||||||||||||||
67 | 31 | UCSF, NAC (N-Acetyl Cysteine) | Glucose regulation Anti-inflammatory Mitochondria | USA | RR | 2 | Active, Not Recruiting | 1.5 | Available Now OTC | MS | 2 | 1.5 | 6 | 98 | 2022-02-16 | 2027-02 | 2027-02 | ||||||||||||||
68 | 32 | Alpha Lipoic Acid Info | Neuroprotective Slows brain atrophy | USA | SP | 2 | Completed Published 2017. | 3 | Available Now OTC | MS | 2 | 1.5 | 6 | ||||||||||||||||||
69 | 33 | TUDCA Bile acid supplement Info. | Neuroprotective Anti-inflammatory | USA | SP | 1/2 | Completed Published 2024. | 5.5 | Available Now OTC | MS | 2 | 1.5 | 6 | 2018-06-19 | 2022-04-28 | 2022-07-05 | |||||||||||||||
70 | 34 | Andrographis | Remyelination | RR | 2 | Completed Published | 3 | Available Now OTC | MS | 2 | 1.5 | 6 | 36 | 2020-09-22 | 2027-02-22 | 2027-05-31 | |||||||||||||||
71 | 35 | GeNeuro, Temelimab | Neuroregenerative Immunomodulator | Many | Treat | 2 | Completed Oct 2023 Published | 4 | 2030 | MS ALS LCovid | 2 | 2 | 8 | ||||||||||||||||||
72 | The TAF-MS study: Tenofovir alafenamide fumarate (TAF) for EBV in MS Info & Trials | EBV Antiviral | Norway | RR | Treat | Pilot | Recruiting | 3 | 2029 | MS | 2 | 2.5 | 10 | ||||||||||||||||||
73 | 36 | Harvard, Antivirals for EBV in MS | EBV Antiviral | USA Harvard | RR | Treat | Pilot | Completed | 4 | 2030 | MS | 2 | 2.5 | 10 | 50 | 2023-06-05 | 2025-06-04 | 2025-12-31 | |||||||||||||
74 | 37 | Haukeland Univ. Intrathecal Stem Cells Trial | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | Norway | SP | 1/2 | Active, Not Recruiting | 4 | 2030 | MS | 2 | 2.5 | 10 | 18 | 2021-08-09 | 2024-10-04 | 2025-01-04 | ||||||||||||||
75 | 38 | Umbilical Cord Stem Cells IV & Intrathecal (UMSC01) Trial | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | Taiwan | RR | 1/2 | Recruiting | 5 | 2031 | MS | 2 | 2.5 | 10 | 41 | 09/08/2023 | 12/31/2026 | 2026-12-31 | ||||||||||||||
76 | 39 | Intrathecal Amniotic Fluid Stem Cells for Progressive MS Trial | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | USA NC | SP PP | 1/2 | Withdrawn | 5 | 2031 | MS | 2 | 2.5 | 10 | 20 | 2026-02-01 | 2026-08-01 | 2026-11-01 | ||||||||||||||
77 | 40 | Extracorporeal Photopheresis (ECP) Info1 Info2 Trial. | Neuroregenerative Anti-inflammatory Immunomodulator | UAE | SP | 1/2 | Active, Not Recruiting | 3.5 | 2029.5 | MS | 2 | 2.5 | 10 | 15 | 2022-03-26 | 2025-03 | 2025-06 | ||||||||||||||
78 | 41 | Oculis, OCS-05 Info Trial | Neuroregenerative Anti-inflammatory | France | Optic Neuritis | 2a | Recruiting | 5 | 2031 | MS ON PD Glaucoma Epilepsy | 2 | 2 | Orphan drug designation | 1 | 9 | 2022-12-19 | 2024-09-16 | 2024-09-16 | |||||||||||||
79 | 42 | Dendritic Cells Therapy Combined With Immunomodulatory Treatment Trial | MBP-tolerizing | Spain | RR | Treat | 2 | Active, Not Recruiting | 4 | 2030 | MS | 2 | 2 | 8 | 45 | 2020-01-27 | 2025-06 | 2025-06 | |||||||||||||
80 | 43 | Alumis Inc., A-005 Info 2026 | TYK2 Inhibitor fully CNS-penetrant ↓ Microglial Activity Anti-inflammatory | USA | MS | 2 | Starts 1st half 2026 | 5 | 2031 | MS PD | 2 | 2 | 8 | ||||||||||||||||||
81 | 44 | Sudo Bio, SUDO-550 Info | TYK2 Inhibitor fully CNS-penetrant ↓ Microglial Activity Anti-inflammatory | USA | MS | 1 | Starts 2nd half 2026 | 4 | 2030 | PMS | 2 | 2 | 8 | 2023-11-06 | 2025-08 | 2025-09 | |||||||||||||||
82 | 45 | Ifenprodil Trial | Remyelination | France | RR | 2 | Not Yet Recruiting | 5 | 2031 | MS | 2 | 2 | Orphan drug designation | 1 | 9 | 60 | 2024-03-01 | 2027-03-01 | 2027-06-01 | ||||||||||||
83 | 46 | Low Dose Naltrexone Trial Info on LDN & Prescribers | Anti-inflammatory | Many | ALL | 2 | Recruiting or Off-label prescription | 3 | 2029 | MS LCovid ME/CFS | 2 | 1.5 | Orphan drug designation | 1 | 6 | ||||||||||||||||
84 | 47 | MediciNova, Ibudilast MN-166 | Neuroprotective Anti-inflammatory Slow-brain-atrophy | USA | SP PP | 2 | Completed Published. 2018 2024. | 3 | 2029 | MS | 2 | 1.5 | 6 | ||||||||||||||||||
85 | 48 | Hydroxychloroquine HCQ | ↓ Microglial Activity Delays progression | Canada | PP | 2 | Off-label Published 2022 2023. | 4 | 2030 | MS RA | 2 | 1.5 | 6 | ||||||||||||||||||
86 | 49 | Rapamycin | Inhibits mTOR Less plaques, Improve EDSS, Regulatory T-cells Anti-inflammatory | USA | RR | Treat | Pilot | Completed Published 2018 | MS LCovid ME/CFS | 1 | 1.5 | 2 | 2018-06-19 | 2022-04-28 | 2022-07-05 | 59 | |||||||||||||||
87 | 50 | Spinal Cord Neuromodulator (SCONE™) for Neurogenic Bladder Info Trial | Spinal cord neuromodulation | USA Canada India | ALL | 2 | Recruiting | 3 | 2029 | MS SCI Stroke | 2 | 1.5 | Orphan drug designation | 1 | 7 | ||||||||||||||||
88 | 51 | TAURUS2 Magnetic Stim Myelin Info Trial | Remyelination | Australia | ALL | 2 | Recruiting | 3 | 2029 | MS | 2 | 1.5 | 6 | 108 | 2024-11-22 | 2024-08-2024 | |||||||||||||||
89 | 52 | Transcranial Magnetic Stimulation There are 10 trials . | Depression | ALL | Recruiting | Trials or Avilable Now | 2 | 1.5 | 6 | ||||||||||||||||||||||
90 | 53 | SetPoint System Vagus Nerve Stimulation for Remyelination Info Trial | Remyelination | USA | RR | Pilot | Recruiting Q4 2025 | 8 | 2034 | MS RA | 0 | 2.5 | 7 | ||||||||||||||||||
91 | 54 | Noninvasive Vagal Nerve Stimulation (VANISH-MS) Info Trial | Neuroplasticity Motor Function | USA NY | ALL | Pilot | Recruiting | 5 | 2031 | 0 | 2 | 6 | 30 | 2025-02-05 | 2025-02-05 | 2026-05-05 | |||||||||||||||
92 | 55 | Vagus Nerve Stimulation for Functional Recovery Info Trial | Neuroplasticity Motor Function | USA CO | ALL | Pilot | Recruiting | 5 | 2031 | Long Covid ME/CFS | 0 | 2 | Breakthrough Device | 2 | 6 | 55 | 2025-01-05 | 2025-06-05 | |||||||||||||
93 | 56 | Acute Intermittent Hypoxia Trial | Neuroplasticity Motor Function | USA Chicago | RR | 2 | Completed Published 2024. | 3 | 2029 | MS | 2 | 1.5 | 6 | 21 | 2024-04-30 | 2026-01-01 | 2027-01-01 | ||||||||||||||
94 | 57 | New Gadolinium-Free MRI Contrast Agent - RVP-001 | A safey trial to test an alternative to gadolinium-based contrast agent | USA CT MA | All | 2 | Recruiting | 2 | |||||||||||||||||||||||
95 | 58 | TG Therapeutics Azer-cel Anti-CD19 CAR-T Cell Info Trial | What is CAR-T Cell Allogeneic CAR-T Cell Therapy - Immune System Reset | USA La Jolla CA | SP PP | Treat | 1 | Recruiting | 6 | 2032 | MS | 1.5 | 3 | 1 | 8 | 32 | 5/6/2025 | 06/01/2027 | 2026-12 | 2029-01-01 | |||||||||||
96 | 59 | Kyverna, KYV-101 CAR-T Cell Trial Early Results | Autologus CAR-T Cell Therapy - Immune System Reset | USA Stanford | SP PP | Treat | 1 | Recruiting | 6 | 2032 | MS | 1.5 | 3 | 1 | 8 | 12 | 4/10/2024 | 06/01/2027 | 2027-06 | ||||||||||||
97 | 60 | KernalBio, KR-402 CAR-T therapy w/ NO chemo | Autologus CAR-T Cell Therapy - Immune System Reset - No chemo | USA Stanford | PMS | Treat | 1 | Planned | 7 | 2033 | MS | 1.5 | 3 | 7 | |||||||||||||||||
98 | 61 | Kyverna, KYV-101 CAR-T Cell Trial Early Results | Autologus CAR-T Cell Therapy - Immune System Reset | USA UCLA | SP PP | Treat | 1 | Active, Not Recruiting | 6 | 2032 | MS | 1.5 | 3 | 7 | 10 | 6/20/2024 | 06/01/2026 | 2027-06 | |||||||||||||
99 | 62 | Novartis, YTB323 CAR-T Cell RRMS Trial Trial | Autologus CAR-T Cell Therapy - Immune System Reset | Australia Europe | RR | Treat | 1/2 | Recruiting | 6 | 2032 | MS | 1.5 | 3 | 7 | 28 | 2/24/2025 | 10/01/2030 | 10/01/2030 | |||||||||||||
100 | 63 | AstraZeneca, AZD0120 (ZENITH) CAR-T Cell Trial | Autologus CAR-T Cell Therapy - Immune System Reset | Australia USA Canada | ALL | Treat | 1b | Recruiting | 6 | 2032 | MS | 1.5 | 3 | 7 | 24 | 12/9/2025 | 12/07/2028 | 12/07/2028 | |||||||||||||
101 | 64 | Bristol Myers, (CC-97540) CAR-T Trial | Autologus CAR-T Cell Therapy - Immune System Reset | USA | SP PP | Treat | 1 | Recruiting | 6 | 2032 | MS MG | 1.5 | 3 | 7 | 120 | 03/28/2024 | 2027-07-15 | 2027-07-15 | |||||||||||||
102 | 65 | University College London Hospital, AUTO1-MS1 Obe-cel CAR-T Info Trial | Autologus CAR-T Cell Therapy - Immune System Reset | UK London | SP PP | Treat | 1 | Recruiting | 6 | 2032 | MS MG | 1.5 | 3 | 7 | 18 | 2025-08-04 | 2029-08-15 | 2029-08-15 | |||||||||||||
103 | Cabaletta Bio, CABA-201 (RESET-MS) CAR-T Cell Trial | Autologus CAR-T Cell Therapy - Immune System Reset | TBD | RR SP PP | Treat | 1/2 | Not Yet Recruiting | #VALUE! | #VALUE! | MS MG SLE | 2 | 3 | Fast Track | 12 | 12 | 2026-06-01 | 2028-09-01 | 2029-10 | |||||||||||||
104 | 66 | Iaso, Eque-cel CAR-T Interim Results Trial | Autologus CAR-T Cell Therapy - Immune System Reset | China | SP PP | Treat | 1 | Recruiting | 6 | 2032 | MS | 1.5 | 3 | 7 | 36 | 2020-09-22 | 2027-02-22 | 292 | Total | ||||||||||||
105 | 68 | Abata, ABA-101 Info Trial | Regulatory T-cells (Tregs) Remyelination | USA | SP PP | 1 | Completed 2024 | 6 | 2032 | MS | 1 | 3 | Fast Track | 3 | 6 | ||||||||||||||||
106 | 69 | Anokion, ANK-700 Inverse Vaccine Trial Results | Immune-tolerance | USA | RR | Treat | 1 | Completed Published. | 5 | 2031 | MS CD T1D | 1.5 | 2.5 | Break- through Therapy | 3 | 9 | |||||||||||||||
107 | 70 | Lapix, LPX-TI641 Info Trial | Iimmune-tolerance | USA, Jordan | ALL | 1 | Completed Nov 2024 | 5 | 2031 | MS NMOSD MOGAD RA PsA | 1.5 | 2 | 5 | 2023-10-30 | 2024-04-15 | 2024-08-01 | |||||||||||||||
108 | 71 | Fibrobiologics CYMS101 Info | Remyelination | USA | RR | 1 | Completed 04/05/2025 | 6 | 2032 | MS DDD DWC SLE | 1.5 | 2.5 | 6 | ||||||||||||||||||
109 | 72 | FSD Pharma, Lucid-MS Info Trial | Non-immunomodulatory Remyelination | Canada | RR | 1 | Completed 12/23/2025 | 6 | 2032 | MS | 1.5 | 2 | 5 | 16 | 2024-09-28 | 2025-01-24 | 2025-01-24 | ||||||||||||||
110 | 73 | Sudo Biosciences, SUDO-550 TYK2 Inhibitor Trial | ↓ Microglial Activity Neurovascular Anti-inflammatory | RR SP PP | 1 | Completed Nov 2025 Ph 2 planned Q2 2026 | 6 | 2032 | MS | 1.5 | 2.5 | 6 | |||||||||||||||||||
111 | 74 | Alumis, A-005 TYK2 Inhibitor Trial | ↓ Microglial Activity Neurovascular Anti-inflammatory | 1 | Completed 12/19/2024 | 6 | 2032 | MS | 1.5 | 2.5 | 6 | ||||||||||||||||||||
112 | 75 | Brenig, BT-409 Info | Blocks NLRP3 inflammasome Anti-inflammatory | Healthy volunteers | 1 | Planned | 8 | 2034 | MS | 1.5 | 2.5 | 6 | |||||||||||||||||||
113 | 76 | Neuron23, NEU-627 TYK2 Inhibitor Info Trial | ↓ Microglial Activity Neurovascular Anti-inflammatory | New Zealand | Healthy volunteers | 1 | Recruiting | 7 | 2033 | MS PD | 1 | 2 | 2 | 2025-06-02 | 2025-11 | 2025-11 | |||||||||||||||
114 | 77 | Allogenic Adipose MSC Stem Cells Intrathecal for PPMS (MAESTRO-4MS) Trial | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | France | PP | 1 | Recruiting | 6 | 2032 | MS | 1 | 2.5 | 3 | 10 | 2025-03-06 | 2029-12-01 | 2029-12-01 | ||||||||||||||
115 | 78 | ImStem, Stem Cells Info Trial | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | USA Georgia | RR SP | 1 | Recruiting | 6 | 2032 | MS | 1 | 2.5 | 3 | 30 | 2021-08-31 | 2027-04-01 | 2027-04-01 | ||||||||||||||
116 | 79 | Neural Stem Cells Brain Injections Info1 Info2 Trial. | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | USA CO Italy | SP | 1 | Completed Published 2023 | 5 | 2031 | MS | 1 | 2.5 | 3 | 15 | 2017-09-09 | 2021-05-29 | 2021-05-29 | ||||||||||||||
117 | 80 | Duke Univ, Stem Cells Trial | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | USA | PP | 1 | Recruiting | 6 | 2032 | MS | 2 | 2.5 | 10 | 20 | 2021-01-24 | 2025-08-30 | 2025-08-30 | ||||||||||||||
118 | 81 | Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration MS & ALS (CONTRASTOME) Trial | Neuroregenerative Anti-inflammatory ↓Microglial Activity MBP-tolerizing | Italy | ALL MS & ALS | Pilot | Recruiting | 7 | 2033 | MS ALS | 1 | 2.5 | 3 | 60 | 2025-01-17 | 2026-03-31 | 2026-09-30 | ||||||||||||||
119 | 82 | Ixazomib SIZOMUS Trial Info | Immunomodulator | UK London | ALL | 1 | Recruiting | 5 | 2031 | MS Cancer | 1 | 2 | 2 | 72 | 2020-08-20 | 2026-07-31 | 2026-07-31 | ||||||||||||||
120 | 83 | Indapta, IDP-023 (natural killer cells) + Ocrevus Trial Info | Remove pathogenic immnue cells that cause inflammation | USA | SP PP | Treat | 1 | Suspended 2025 May resume | 6 | 2032 | MS Cancer | 1 | 2 | 2 | 34 | 2026-06-30 | 2026-12-31 | 2028-12-31 | |||||||||||||